MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research to evaluate a number of intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Main trial objectives have been To judge the security and tolerability of sifalimumab in dermatomyositis or polymyosit